IRD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IR

Mkt Cap

$319.9M

Volume

2.40M

Next Earnings

November 11th

Loading chart

IR

IRDOpus Genetics, Inc. Common Stock

IRD

Pay with—

Available Balance0.00

IR

Mkt Cap

$336.9M

Volume

2.40M

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaOpus Genetics announced FDA approval of phentolamine ophthalmic solution 0.75% (RYZUMVI®) for treating presbyopia in adults, expanding its previous indication for pharmacologically-induced mydriasis. The approval was supported by positive Phase 3 VEGA-2 and VEGA-3 trial results and will trigger a milestone payment from commercial partner Viatris Inc. Presbyopia affects approximately 90% of U.S. adults over 45, and the drug offers a non-invasive treatment option.GlobeNewswire Inc. · Oct 16, 2026

Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology ConferencesOpus Genetics announced plans to present topline clinical data from Phase 1/2 Cohort 1 of its OPGx-BEST1 gene therapy program during an investor conference call on September 9, 2026. The company will also present full clinical datasets and additional analyses at several upcoming ophthalmology conferences including Euretina, Retina in Rio, and FLORetina.GlobeNewswire Inc. · Sep 2, 2026

Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal DiseaseOpus Genetics announced successful FDA alignment on its Phase 3 clinical trial design for OPGx-LCA5, a gene therapy for LCA5-associated inherited retinal disease. The FDA indicated the company may submit a Biologics License Application based on 6-month efficacy data, with 12-month durability data provided during review. Phase 3 dosing is expected to begin in Q4 2026, with seven of eight planned participants already enrolled.GlobeNewswire Inc. · Jul 6, 2026

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease ExpertsOpus Genetics announced a virtual R&D Science Forum scheduled for June 16, 2026, featuring leading ophthalmology experts to discuss the company's gene therapy pipeline for inherited retinal diseases. The forum will highlight three programs entering clinical testing targeting RDH12, MERTK, and RHO mutations, along with updates on ongoing LCA5 and BEST1 clinical programs and market opportunities in the IRD space.GlobeNewswire Inc. · Jun 2, 2026

Opus Genetics to Present at the 2026 Jefferies Global Healthcare ConferenceOpus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced it will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The company is advancing seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1 targeting different retinal disorders.GlobeNewswire Inc. · May 27, 2026

Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare ConferenceOpus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, announced that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on May 19, 2026. The company is advancing its pipeline of seven AAV-based programs, with lead candidates OPGx-LCA5 and OPGx-BEST1.GlobeNewswire Inc. · May 13, 2026

Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightThe presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.GlobeNewswire Inc. · May 11, 2026

Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingOpus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and advancing phentolamine as a small-molecule therapy.GlobeNewswire Inc. · Apr 10, 2026

Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland CapitalOpus Genetics secured up to $155 million in non-dilutive funding from Oberland Capital Management, including an upfront $35 million and $5 million equity investment. The financing extends the company's cash runway into 2029 and will accelerate clinical development of gene therapy programs for inherited retinal diseases, with three additional programs expected to enter clinical testing over the next year. Three-month topline results from OPGx-BEST1 Phase 1/2 trial remain on track for mid-2026.GlobeNewswire Inc. · Apr 6, 2026

Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026Opus Genetics, a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, has been recognized by Fast Company as one of the world's most innovative companies in the Biotech category for 2026. The company has advanced a pipeline of gene therapies including OPGx-BEST1 and OPGx-LCA5, employing a patient-centered approach to development.GlobeNewswire Inc. · Mar 24, 2026

to start trading

IR

IRDOpus Genetics, Inc. Common Stock

IRD

Pay with—

Available Balance0.00

Your PositionYou don't own any IRD yet.

Related Tickers

Earnings